Ziegelhöffer A, Bundgaard H, Ravingerová T, Tribulová N, Enevoldsen M T, Kjeldsen K
Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovakia.
Diabetes Nutr Metab. 2003 Aug;16(4):222-31.
AIMS/HYPOTHESIS: In comparison with healthy controls, rats with streptozotocin-induced diabetes exhibit retarded gain in body weight. This is generally attributed to lowered protein synthesis resulting from abnormal metabolism. Furthermore, decreased abundance and activity of Na,K-ATPase in heart and skeletal muscle has been described. However, decreased gain in body weight per se is accompanied by a down-regulation of skeletal muscle Na,K-ATPase. Thus, the aim of the present study was to evaluate cardiac Na,K-ATPase in semi-starvation and diabetes.
Diabetes was induced in male Wistar rats with streptozotocin. In healthy parallel running control rats body weight gain was kept reduced by limited food intake.
Semi-starved and diabetic rats demonstrated 18 and 16% (p < 0.05) retarded gain in body weight after 63 days. As compared to semi-starved rats, diabetic animals exhibited a 59-273% (p < 0.05) increase in glucose, glycohaemoglobin, triglyceride and cholesterol plasma levels. Activity of heart K-pNPPase, reflecting Na,K-ATPase, in crude membrane homogenates was reduced by 29 and 10% (p < 0.05) by diabetes and semi-starvation. The age-dependent reduction in heart K-pNPPase in normal controls was 6%. After subtracting the age-dependent change, the reductions were 25 and 4% in diabetes and semi-starvation, respectively. After subtracting the semi-starvation-associated change, the diabetes-induced reduction was 22-27%. The reduction was in accord with measurements of Na,K-ATPase activities in partially purified membranes, Na,K-ATPase isoforms and cytochemical evaluations. Expressed per heart, the reduction in Na,K-ATPase was 30%.
CONCLUSIONS/INTERPRETATION: Streptozotocin-induced diabetes selectively reduces heart Na,K-ATPase concentration by around 1/4, which reduces the capacity of the heart for maintaining K- and Ca-homeostasis. This may pose a risk of arrhythmias and may be associated with heart failure in diabetic cardiomyopathy.
目的/假设:与健康对照组相比,链脲佐菌素诱导的糖尿病大鼠体重增加迟缓。这通常归因于异常代谢导致蛋白质合成降低。此外,已有研究描述了心脏和骨骼肌中钠钾ATP酶的丰度和活性降低。然而,体重增加本身的减少伴随着骨骼肌钠钾ATP酶的下调。因此,本研究的目的是评估半饥饿和糖尿病状态下的心脏钠钾ATP酶。
用链脲佐菌素诱导雄性Wistar大鼠患糖尿病。在健康的平行对照大鼠中,通过限制食物摄入量使体重增加减少。
63天后,半饥饿和糖尿病大鼠的体重增加分别迟缓了18%和16%(p<0.05)。与半饥饿大鼠相比,糖尿病动物的血糖、糖化血红蛋白、甘油三酯和胆固醇血浆水平升高了59 - 273%(p<0.05)。反映钠钾ATP酶的心脏K-pNPPase在粗膜匀浆中的活性,因糖尿病和半饥饿分别降低了29%和10%(p<0.05)。正常对照组中,心脏K-pNPPase随年龄的降低为6%。减去年龄相关变化后,糖尿病和半饥饿状态下的降低分别为25%和4%。减去与半饥饿相关的变化后,糖尿病诱导的降低为22 - 27%。这种降低与部分纯化膜中钠钾ATP酶活性、钠钾ATP酶同工型的测量以及细胞化学评估结果一致。以心脏为单位计算,钠钾ATP酶的降低为30%。
结论/解读:链脲佐菌素诱导的糖尿病选择性地使心脏钠钾ATP酶浓度降低约1/4,这降低了心脏维持钾和钙稳态的能力。这可能会带来心律失常的风险,并且可能与糖尿病性心肌病中的心力衰竭有关。